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Elevated MYC expression sensitizes tumor cells to apoptosis but the therapeutic potential of this
mechanism remains unclear. We find, in a model of MYC-driven breast cancer,
that pharmacological activation of AMPK strongly synergizes with BCL-2/BCL-XL inhibitors to
activate apoptosis. We demonstrate the translational potential of an AMPK and BCL-2/BCL-XL
co-targeting strategy in ex vivo and in vivo models of MYC-high breast cancer. Metformin
combined with navitoclax or venetoclax efficiently inhibited tumor growth, conferred survival
benefits and induced tumor infiltration by immune cells. However, withdrawal of the drugs
allowed tumor re-growth with presentation of PD-1+/CD8+ T cell infiltrates, suggesting immune
escape. A two-step treatment regimen, beginning with neoadjuvant metformin+venetoclax to
induce apoptosis and followed by adjuvant metformin+venetoclax+anti-PD-1 treatment to
overcome immune escape, led to durable antitumor responses even after drug withdrawal. We
demonstrate that pharmacological reactivation of MYC-dependent apoptosis is a powerful
antitumor strategy involving both tumor cell depletion and immunosurveillance.
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MYC is a multifunctional oncogenic transcription factorthat is frequently overexpressed in cancer. The MYCgene locus is amplified in about 16% of all breast
tumors and about one-third of breast tumors overexpress MYC
mRNA1–3. In a genetic landscape study of breast cancer, MYC
stands out as one of the seven key driver cancer genes4.
MYC protein expression is also elevated via altered post-
translational mechanisms and, altogether, about half of breast
cancers display elevated MYC protein expression5. MYC over-
expression and amplification are associated with breast tumor
progression and increased risk of relapse and death3,6.
When overexpressed, MYC can promote transcription, not
only via its canonical binding sites, but also by occupying low
affinity promoters. Such “promoter invasion” may endow cells
with new tumor-specific phenotypes7, including insensitivity to
proliferation-restricting signals, altered cell metabolism in sup-
port of continuous growth, and effects on the tumor micro-
environment8. However, deregulated MYC expression also
creates cancer vulnerabilities that can be exploited therapeutically.
For example, the effects of oncogenic MYC on cell metabolism,
host-microenvironment communication, and immunoregulation
have all been considered as potential nodes for targeting MYC
indirectly9–12.
Perhaps the most interesting vulnerability from a therapeutic
standpoint is the strong pro-apoptotic activity of MYC13,14,
which involves induction or activation of pro-apoptotic BCL-2
family members, such as BIM, BAK, and BAX, or reduction of
anti-apoptotic members, like BCL-2 and BCL-XL. Independently
or in combination, these changes can “prime” and activate the
intrinsic (mitochondrial) pathway of programmed cell death13.
Findings in mouse tumor models have indicated that MYC’s
apoptotic function normally presents a major roadblock to tumor
formation15, but that overexpression of BCL-2 or BCL-XL or loss-
of-p53 efficiently rescues tumors from apoptosis without reducing
the tumor-promoting functions of MYC13,16.
The development of small-molecule BH3 mimetics, which bind
and neutralize anti-apoptotic BCL-2 family proteins, has moti-
vated attempts to therapeutically reactivate the apoptotic poten-
tial of MYC in tumors. Optimally, pharmacological reactivation
of MYC-dependent apoptosis would eradicate tumors without
harming normal cells expressing physiological levels of MYC.
BH3 mimetics such as the BCL-2/BCL-XL inhibitor ABT-737, its
orally bioavailable derivative ABT-263/navitoclax, or BCL-2-
specific ABT-199/venetoclax, have shown an ability to restrain
lymphomagenesis in Eμ-Myc mouse models of lymphoma. Fur-
thermore, improved activity has been obtained by combining
BH3 mimetics with standard chemotherapy17, proteasome inhi-
bitors, or histone deacetylase inhibitors18,19. These findings,
while encouraging, underscore the pressing need to find efficient
mechanism-based approaches to fully reactivate apoptosis in
cancer cells and maximize therapeutic benefit.
We explored the antitumor effects of BCL-2/BCL-XL inhibition
using ABT-737 in a mouse model of Myc-driven breast cancer.
Although ABT-737 was sufficient to induce apoptosis and reduce
tumor growth as monotherapy, it failed to provide survival
benefit. Our efforts to identify optimal companion drugs unex-
pectedly exposed strong apoptotic synergy with agents that
induce AMP-activated protein kinase (AMPK) activation. Robust
activation of MYC-associated apoptosis by combined BCL-2/
BCL-XL inhibition and AMPK activation suppressed tumor
growth, offered survival benefits, and increased the infiltration
and activity of immune cells in the tumor tissue. Tumors that
grew post-treatment were found to be infiltrated by PD-1-positive
cytotoxic T cells, consistent with the emergence of post-therapy
immune exhaustion. More durable therapeutic effects were
obtained when BCL-2/BCL-XL inhibition and AMPK activation
in the adjuvant setting were supplemented with anti-PD-1 ther-
apy. These findings demonstrate that MYC-induced apoptotic
sensitivity is an actionable tumor vulnerability, especially when
combined with immune checkpoint blockade.
Results
MYC and the anti-apoptotic BCL-2 proteins in breast cancer.
To determine whether primary breast cancer could be targeted by
a therapeutic strategy that reactivates MYC’s apoptotic potential
via BH3 mimetics, we assessed the expression of MYC, BCL-2,
BCL-XL, and MCL-1 using a tissue microarray (TMA) of 231
primary breast cancer samples. Immunohistochemistry revealed a
widespread nuclear staining of MYC in almost half of the samples
(Fig. 1a) (MYC-high, >50% cells positive). Surprisingly, >40% of
the samples were mostly negative for MYC expression (MYC-low;
<20% cells positive), and only a minor fraction of the samples fell
in-between the MYC-high and MYC-low categories. Thus, MYC
expression is noticeably dichotomous in primary breast cancer.
The expression levels of cytosolic BCL-2 family proteins were
defined as negative, weak, intermediate, or strong, and the results
of both the MYC and the BCL-2 family stainings were analyzed
across the major breast cancer subtypes. BCL-2, BCL-XL, and
MCL-1 proteins were expressed at intermediate/strong levels in
≥37% of cases in each subtype (Supplementary Figure 1A). More
than half of the breast cancers with MYC-high status expressed
a high level of BCL-2, BCL-XL, or MCL-1 (Fig. 1b). Thus, high
expression levels of MYC and anti-apoptotic BCL-2 proteins are
common features in breast cancer.
BH3 mimetic ABT-737 inhibits Myc-driven mammary tumor
growth. To study whether simultaneous neutralization of Bcl-2
and Bcl-XL by the prototype BH3 mimetic ABT-737 reactivates
Myc-associated apoptosis in vivo, we utilized an autochthonous
WapMyc mouse model of breast cancer. In this model, lactogenic
hormones activate the Wap promoter during late pregnancy,
leading to high Myc expression in the luminal cells of the
mammary gland and the formation of solitary adenocarcinomas
within 2–3 months20,21. WapMyc tumor cells express high levels
of Bcl-2, Bcl-XL and Mcl-1 (Fig. 1d), and are sensitive to ABT-737
ex vivo (Fig. 1e, Supplementary Figure 1B–C). Tumor-bearing
WapMyc mice received daily administration of ABT-737 for
21 days and were followed up for another 21 days (Fig. 1c). ABT-
737 treatment increased apoptosis in tumors, although overall
apoptosis was low (<5%), perhaps due to the rapid clearance of
apoptotic cells in live tissues (Fig. 1f, Supplementary Figure 1D).
ABT-737 inhibited tumor growth during the first 12 days of
treatment (Fig. 1g), after which time the first animals had to be
killed. Therefore, at later time points the average tumor volume
does not indicate tumor growth rates reliably (Fig. 1g left, gray
area). To estimate the tumor growth rates throughout the
experimental period, we used a mixed-effects modeling frame-
work that excludes killed animals from the experiment. While
ABT-737 inhibited tumor growth over the whole 21-day treat-
ment period (Supplementary Figure 1E), there was no statistically
significant difference in the overall survival between the control
and ABT-737-treated groups (Fig. 1g, right). Interestingly, lung
metastases were observed in only 27% of the ABT-737-treated
mice, compared to 50% of mice in the control group (Fig. 1h).
To test the efficacy of ABT-737 in parallel cohorts, we
developed an orthotopic WapMyc tumor syngraft model. Tumor
cell suspensions from donor FVB mice were grafted bilaterally
to cleared fat pads of the syngeneic host mice. The syngrafted
tumors appeared 2 weeks after the transplantations and retained
their original histological adenocarcinoma phenotype with high
Myc expression (Fig. 1i–j). ABT-737 treatment-induced apoptosis
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in these tumors (Supplementary Figure 1F–G) and slowed tumor
growth at early stages of tumor formation (Fig. 1k, left). Once
again there was no difference in the overall survival between the
control and the ABT-737-treated groups (Fig. 1k, right).
In summary, ABT-737 induces apoptosis, inhibits the growth
of primary tumor and its dissemination to distant tissues.
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Co-targeting AMPK and BCL-2/-XL sensitizes to MYC apop-
tosis. To identify drugs that could enhance the apoptotic effect of
BCL-2/BCL-XL inhibition, while still preserving MYC-dependence,
we analyzed the effect of ABT-737 in combinations with small-
molecules that target cancer survival pathways (Fig. 2a). For the
assays, we employed non-transformed MCF10A mammary epi-
thelial cells expressing a conditionally active form of MYC
(MycER)14. The apoptotic potential of single-agent and combina-
tion treatments was tested with and without MYC activation
(Fig. 2b–c). All tested compounds potentiated the apoptotic action
of ABT-737 but the level of MYC-dependence varied. Combina-
tions with BEZ-235 and MK2206 were active regardless of MYC
status (Fig. 2c) and not investigated further. Interestingly, a strict
MYC-dependency was observed for apoptosis induced by Nutlin-3a
and PRIMA-1, which both act by inducing p53 activity, and A-
769662, a compound that activates AMPK by an allosteric
mechanism (Fig. 2d). These observations are consistent with earlier
findings showing that the MYC-dependent pro-apoptotic action of
AMPK is coupled with p53 in MCF10A cells22. A-769662 did not
induce cell death without sensitization by MYC and ABT-737, even
at high concentrations (Fig. 2e–f). Metformin, a commonly used
type II diabetes drug that also activates AMPK, induced similar
MYC-dependent apoptosis when combined with ABT-737
(Fig. 2g–h).
To further examine whether high endogenous expression of
MYC induces apoptotic sensitivity, we employed a dCas9VP192-
assisted transcriptional activation system to upregulate MYC
expression from its own locus23. In this system, guide-RNAs
targeted to MYC promoter-proximal areas recruit a fusion
protein comprising dead CRISPR-associated protein (dCas9)
and repeats of Herpes simplex virus protein-16 transactivation
domain (VP192) (Fig. 2i). Chemical activation of the MYC
promoter-guided dCas9VP192-induced endogenous MYC
expression (Fig. 2i, Supplementary Figure 2A) and sensitized
MCF10A cells to apoptosis by ABT-737+A-769662 (Fig. 2j).
Together, these results establish a role for MYC in rendering cells
sensitive to combined AMPK activation and BCL-2/BCL-XL
inhibition.
AMPK-induced BIM mediates apoptosis. We asked whether
AMPK sensitizes to ABT-737 by reducing the expression of anti-
apoptotic BCL-2 family proteins like MCL-1, a known resistance
factor for BH3 mimetics24. However, A-769662 did not alter
the levels of BCL-2, BCL-XL, or MCL-1 (Fig. 3a, Supplementary
Figure 2B). To explore the role of pro-apoptotic BCL-2 proteins,
we silenced the expression of BH3-only proteins in MCF10A cells
prior to inducing apoptosis with the well-established synthetic-
lethal combination of MYC and TRAIL (Fig. 3b, Supplementary
Figure 2C)14,25. Apoptosis was completely abolished by the loss of
BID, consistent with its role as the main mediator of TRAIL-
induced apoptosis. The only other BH3-only protein as crucial for
MYC-TRAIL-induced apoptosis was BIM (Fig. 3b), which has
been suggested to drive MYC-dependent apoptosis also in other
studies26 (Supplementary Figure 2D).
We next studied whether AMPK activation upregulates BIM.
MCF10A cells express two BIM isoforms, corresponding to
alternatively spliced isoforms, BIML and BIMEL. These isoforms
differ in their properties, BIML being a more potent activator of
apoptosis than BIMEL27. MYC induced a slight upregulation of
both isoforms, consistent with earlier findings26. Notably, A-
769662 induced a strong upregulation of BIML independent of
MYC expression or the addition of ABT-737 (Fig. 3c). Further-
more, silencing of BIM specifically abolished the AMPK-dependent
enhancement of apoptosis, which establishes BIM as a major
contributor to this mechanism (Fig. 3d, compare to Fig. 2f).
To examine the relevance of these findings in cancer, we
investigated the status of AMPK activity and BIM in a set of
clinical breast cancer samples with known MYC status (Fig. 1a).
Although these analyses suggested no correlation between MYC
and BIM levels or MYC and AMPK activity (detected by
phosphorylated Acetyl-CoA Carboxylase, pACC) (Fig. 3e), they
revealed a strong correlation between AMPK activity and BIM
levels. These results are consistent with the data in Fig. 3c and
suggest that chronically high MYC levels may not be compatible
with high AMPK activity and high BIM levels in tumors, as the
combination would likely induce apoptosis (Fig. 3f). This idea
led to the hypothesis that activation of AMPK could sensitize
MYC-driven tumors to BH3 mimetics.
Apoptosis induction in MYC-positive breast cancer explants.
We next examined whether the AMPK and BCL-2/BCL-XL co-
targeting strategy triggers MYC-dependent apoptosis in human
breast cancer tissue. For this purpose, we established a three-
dimensional (3D) Patient-Derived Explant culture (PDEc) model
of primary breast cancer (Supplementary Figure 3A–C). Ten
breast tumors, three tumor-adjacent areas (adjacent), and three
non-tumor control tissues (reduction mammoplasty) were pro-
cessed and analyzed as in Fig. 4a. Consistent with our earlier
findings suggesting dichotomous expression of MYC in primary
breast cancer samples (Fig. 1a), five out of ten tumor samples
were defined as MYC-high; whereas, the other half of the samples
were MYC-low (Fig. 4b). Comparison of the MYC status in two
original tumor and adjacent tissue samples and their explant
derivatives demonstrated that PDEc culture conditions preserve
their original tumor sample-specific nuclear MYC status
(Fig. 4c–d).
We tested the pro-apoptotic potential of ABT-737+A-769662
combination in PDEcs (Fig. 4e). No apoptotic responses were
Fig. 1 Inhibition of anti-apoptotic BCL-2 proteins by ABT-737 curbs WapMyc-driven mammary tumor growth. a Nuclear expression of MYC in breast
cancer. Representative images from a breast cancer tissue microarray (TMA) immunostained for MYC. Samples that were missing from the TMA slide or
had insufficient clinical diagnosis data, or had inadequate technical quality were excluded from all analyses. b Cross-tabulation of MYC expression against
BCL-2, BCL-XL, or MCL-1 expression status. Gray boxes: Double-positive samples. c ABT-737 treatment protocol for WapMyc-induced autochthonous
mammary adenocarcinoma. Red arrow: start of the treatment. d Upper: Western blot analysis of anti-apoptotic BCL-2 proteins in parallel non-tumor and
tumor glands dissected from the same WapMyc mouse (N= 4 mice). Tubulin: Loading control. Lower: Immunostaining of BCL-XL in a hyperplastic gland
and a tumor gland. Tumor–stroma border indicated with red dotted line. e Flow cytometric quantification of apoptosis in primary cultures. Epithelial cells
were isolated from tumor or non-tumor glands, treated 24 h with 1 μM ABT-737 and stained with Annexin V/PI. Triplicate experiments performed on
control (N= 2) or WapMyc tumor cell isolates (N= 5). Student’s t-test (unpaired), SD. f Quantification of apoptosis in tumor tissue. Positive cells scored
from 16 vehicle and 16 ABT-737-treated tumors. Student’s t-test (unpaired), SD. g Left: Tumor growth during the 21-day treatment period. Arrow: First
mice killed due to tumor burden (Ø > 2 cm). Right: Survival of the mice. h ABT-737 treatment decreases incidence of lung metastases in WapMyc tumor
bearing mice, Student’s t-test (unpaired). i ABT-737 treatment protocol for orthotopically syngrafted WapMyc tumors. jMYC expression pattern in normal
human breast tissue, human breast tumors, and endogenous & syngrafted WapMyc mouse mammary tumors. k Left: Tumor growth during the 21-day
treatment period. Arrow: The first mice sacrificed due to tumor burden (Ø > 2 cm). Right: Survival of the mice
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observed in the non-cancerous samples (Supplementary Fig-
ure 3D). While ABT-737 alone occasionally promoted apoptosis,
the most prominent responses were obtained with the combina-
tion (Fig. 4e–f). Among the combination-treated cultures, the
strongest apoptotic response was observed in PDEcs derived from
MYC-high tumors and the overall difference in apoptosis
between MYC-high and MYC-low PDEcs was statistically
significant (Fig. 4f). Aside from the MYC link, examination of
the samples’ clinical annotations revealed no other significant
correlations with strong apoptotic responses (Supplementary
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Table 1). Consistent with our cell culture findings, A-769662-
induced AMPK activation and BIM upregulation in PDEcs
(Fig. 4g).
Antitumor effects of metformin and BCL-2/-XL inhibition.
Based on the strong signals of activity in PDEcs, we went on to
explore the antitumor activity of combined AMPK activation
and BCL-2/BCL-XL inhibition in vivo. For in vivo testing, we
formulated an “AB” (A: AMPK activator, B: Inhibitor of anti-
apoptotic BCL-2 proteins) regimen. For the “B” component,
we used either ABT-263/navitoclax (ABn) or ABT-199/veneto-
clax (ABv). Navitoclax is an orally bioavailable analogue of ABT-
737 that also inhibits both BCL-2 and BCL-XL, whereas veneto-
clax is a distinct, oral agent that selectively inhibits BCL-2. For
the “A” component, metformin was implemented in place of A-
769662. Metformin is an AMPK-activating agent with a long
history as a type II diabetes drug that has well-established
adverse-effect and safety profiles28. The analysis of four different
BH3 mimetics in combination with either A-769662 or metfor-
min confirmed that metformin has similar apoptosis-potentiating
action as A-769662 (Fig. 5a, Supplementary Figure 4A). Fur-
thermore, metformin in combination with navitoclax (ABn)
showed similar pro-apoptotic activity in MYC-high PDEcs
(Fig. 5b, compare with Fig. 4e).
TNBC is a breast cancer subtype with poor clinical outcome
and commonly elevated MYC levels29. In a panel of 16 TNBC cell
lines the ABn treatment strongly reduced viability in cell lines
with elevated MYC expression. At the low apoptosis-inducing
concentration of navitoclax (EC20), combination with metformin
potentiated apoptosis in 11 out of 11 MYC-positive TNBC cell
lines, whereas no such effect was seen in 4 out of 5 cell lines with
low or undetectable MYC expression (Fig. 5c–e, Supplementary
Figure 4B–C). These experiments confirmed the MYC-associated
apoptotic potential of the AB regimen, supporting its use for
in vivo studies.
To evaluate the antitumor potential of AB treatment in vivo,
we used a patient-derived xenograft (PDX) model based on
graftable samples from a metastatic TNBC. The mammary gland-
grafted TNBC sample formed aggressive tumors that invaded
through the peritoneum and formed multiple metastases in the
abdominal cavity (Fig. 5f). Sequencing of the sample revealed
typical TNBC-associated mutations such as p53 R248W (Supple-
mentary Figure 5A). Passaging in vivo allowed us to generate
mouse cohorts for multiple treatment arms and high MYC
expression was verified in passaged tumors (Fig. 5g). TNBC
samples were transplanted into mammary fat pads and
treatments were initiated 2 weeks post operation. Although
navitoclax or metformin failed to show activity as single
agents, the ABn combination treatment strongly inhibited tumor
growth (Fig. 5h). In addition, ABn treatment significantly
extended the survival of TNBC-grafted mice. Taken together,
the combination of metformin and navitoclax exerts MYC-
associated antitumor activity capable of prolonging the survival
of mice transplanted with a highly aggressive and invasive
TNBC specimen.
ABn does not benefit mice with Myc-low mammary tumors. To
address the importance of high MYC expression for treatment
efficacy, we employed two mouse models of breast cancer with
low MYC expression; the MMTV-PyMT model with tumors
syngrafted to FVB mice and an ER+ PDX model with
tumors grafted to NSG mice. Mice with orthotopically engrafted
tumors were subjected to the ABn as before. In contrast to FVB
WapMYC syngrafts, the FVB MMTV-PyMT tumors did not
respond to navitoclax or metformin, either as single agents or in
combination (Supplementary Figure 5E). Although tumors in the
MYC-low ER+ PDX model responded well to navitoclax as a
single agent (we note that BCL-2 expression is often reported as
enriched in this breast cancer subtype30), combining it with
metformin did not offer any added benefit (Supplementary Fig-
ure 5F). These results are consistent with the notion that high
MYC expression defines tumors that are most likely to respond to
ABn treatment.
ABn activates MYC-dependent immunogenic apoptosis
in vivo. Accumulating evidence indicates that the therapeutic
effects of current anticancer drugs, including chemotherapy, arise
not only from direct tumor cell killing, but also from enhanced
immunoactivation31–33. The immunoactivating signals may
derive from the injured tumor, for example, in the form of lib-
erated pro-inflammatory cytokines32 or via release of tumor
antigens and neoantigens31. Notably, some forms of drug-
induced cell death appear more immunogenic than others34.
To explore whether the ABn treatment promotes immunoac-
tivation, we generated cohorts of immunocompetent WapMyc
tumor syngrafted mice, which were treated with single drugs
or combination (Fig. 6a). In mice, 250 mg/kg/d dosing of
metformin achieves similar drug plasma concentrations as
measured for diabetic patients treated with 2 g/day35,36. The
metformin safety profile allowed dose escalation from the
standard antidiabetic dosage to maximize the apoptotic effects.
Thus, for antitumor treatments the mouse cohorts were treated
with the standard antidiabetic dose of 300 mg/kg/d or with an
escalated 600 mg/kg/d dose. A set of tumors dissected immedi-
ately after the treatments and before the follow-up (on-treatment
samples) exhibited striking AMPK activation, BIM upregulation,
and apoptosis in response to ABn already with the antidiabetic
dose of 300 mg/kg/d (Fig. 6b, Fig. 6c, Supplementary Figure 5B).
The combination treatment triggered notable regions of dying
cells, or “apoptotic ponds” (Fig. 6c), an effect rarely seen in vivo
Fig. 2 AMPK activation potentiates MYC-dependent apoptosis by ABT-737. a Drug-targeted pathways. b Protocol for drug combination testing. MCF10A
MycER cells were allowed to form mammospheres for 24 h. MYC was activated with 100 nM 4OHT for 24 h followed by 24 h incubation with drug
combinations. c Combination drug testing to identify pharmacological triggers of MYC-dependent apoptosis. The drugs were administered as single agents
or as ABT-737 with and without MYC activation. Each drug was tested in two concentrations. N= 3 biological repeats. Student’s t-test (unpaired), SD.
d The relative level of apoptosis with and without MYC activity (+MYC: −MYC ratio). The ratio was calculated from fold-change in c. e Representative
images of drug-treated mammospheres. f, g Sensitization to MYC-dependent apoptosis by 100 nM ABT-737 with either 1 μM A-769662 or 10 mM
metformin. Mammospheres were treated as in b. Student’s t-test (unpaired), N= 3 biological replicates, SD. h Activation of AMPK alone does not sensitize
to MYC-dependent apoptosis. N= 3 biological repeats, SD. i CRISPR/dead-Cas9-mediated transcriptional activation of MYC. HEK293 and MCF10A cells
were transduced with vectors encoding dCas9-VP192 transcription-activating construct and MYC-promoter-targeted guide-RNAs. Western blot analysis
shows MYC expression levels after 72 h treatment with doxycycline (DOX) and trimethoprim (TMP). Lamin B: Loading control. j CRISPR-mediated
induction of endogenous MYC sensitizes cells to apoptosis by ABT-737+A-769662. Mammospheres with and without dCas9-VP192+MYC-gRNA were
treated and analyzed as in b. Student’s t-test (unpaired), N= 3 biological replicates, SD
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due to the rapid clearance of debris by neighboring cells and
macrophages.
Immunohistochemical analysis of the ABn on-treatment tumor
samples revealed significant enrichment of CD4+ T helper cells
and CD8+ cytotoxic T cells (Fig. 6d). Recent investigations have
highlighted the critical role of systemic immune response in
eradication of tumors by immunotherapies37. Examination of
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CD4+ T and NK cells (Fig. 6e), thus suggesting not only local
but also systemic immune activation.
ABn induces T lymphocyte infiltration and exhaustion. In
the experiments with WapMyc tumor syngrafted mice, ABn
treatment significantly inhibited tumor growth in a dose-
dependent manner with no observable adverse effects (Fig. 6f,
Supplementary Figure 5C–D). Importantly, the combination
treatment also prolonged survival. At the end of the follow-up
period, half of the mice that received ABn with the antidiabetic
metformin dose were still alive, in contrast to all other cohorts,
which had no survivors (Fig. 6g). The higher 600 mg/kg/d dose of
metformin together with navitoclax provided a striking survival
benefit, with 75% of the ABn-treated mice surviving over the
study period (Fig. 6h). A survival benefit was also observed in the
cohort receiving the high metformin dose alone, suggesting that
high metformin concentrations may have other therapeutic
effects besides induction of apoptosis.
Although, the ABn treatment controlled tumor growth (Fig. 6f),
it failed to prevent post-treatment tumor recurrence. To explore
why the tumors regrew despite signs of immunoactivation, we
analyzed immune infiltrates in the post-treatment tumors.
Tumors of equivalent size (Ø 2 cm) were isolated after the
treatments and equivalent amounts of tumor mass were
homogenized into single cell suspension for flow cytometric
analysis with panels of immunophenotype-specific antibodies.
The analyses revealed post-treatment persistence and activity of
tumor-infiltrating NK cells (CD3−/NK1.1+), NKT cells (CD3
+/NK1.1+) and CD4+ T cells, and a general enrichment of total
leukocytes in the treated tumors (Fig. 6i). However, the number
of active cytotoxic T cells (CD8+/CD107+) was lower in the
treated tumors in comparison to controls, whereas the opposite
was true for interferon-gamma (IFN-γ)-secreting cytotoxic
T cells, which were observed in higher levels after ABn treatment
(Fig. 6i). IFN-γ secretion by T cells is necessary for T cell activity,
but also promotes T-cell exhaustion and adaptive immune
resistance by upregulating inhibitory PD-1/PD-L1 signaling38,39.
PD-1 is an inhibitory coreceptor found on T lymphocytes that
is responsible for feedback inhibition of T-cell activation34.
We observed increased ratio of PD-1-positive cytotoxic T cells
in the tumors that had been treated with ABn, suggesting the
onset of T-cell exhaustion (Fig. 6j). To summarize, ABn treatment
leads to increased infiltration of tumors by lymphocytes of
both adaptive and innate immunity, with markers of cytolytic
activity and T-cell exhaustion.
ABv with anti-PD-1 provides durable antitumor response. T-
cell exhaustion can occur due to persistent antigen stimulation in
viral infections and is also a key target of immunotherapies for
cancer. Antibodies targeting the PD-1 inhibitory receptor path-
way have demonstrated significant antitumor activity and have
been approved for use in cancer patients31. The observation of T-
cell exhaustion markers post-ABn treatment suggested that more
durable treatment responses could be achieved by combining AB
with anti-PD-1 therapy. For these experiments, new cohorts of
WapMyc-syngrafted mice were generated and treated with ABv,
which includes the BCL-2-specific inhibitor venetoclax (ABT-
199). Venetoclax was chosen here for its translational potential,
as it was recently granted accelerated approval by the FDA for
a cancer indication40 and it also synergized with metformin
to induce MYC-dependent apoptosis (Fig. 5a, Supplementary
Figure 4A).
We hypothesized that AB-induced apoptosis is crucial for
triggering the initial antitumor immunity that is subsequently
blunted by PD-1-dependent immunosuppression. Accordingly, we
designed a preclinical treatment protocol in which ABv was first
administered as a neoadjuvant (pre-surgery) treatment. To avoid
early killing of control mice and to extend the experimental time-
frame, the tumors were surgically resected at the end of the first
treatment period (Fig. 7a). Following surgery, the mice received as
an adjuvant (post surgery) treatment single drugs or ABv, either in
combination with control IgG or anti-PD-1 antibody. Neoadju-
vant ABv significantly inhibited tumor growth, although the effect
was weaker than in previous studies with ABn (Fig. 7b). After
tumor resection, all control mice developed aggressive secondary
tumors in less than 1 week, and had to be killed within 2 weeks
after resection (Fig. 7c–d, see Fig. 7g for survival). Anti-PD-1 as an
adjuvant did not provide any treatment benefit, suggesting that
these tumors were not immunotherapy responsive by default
(Fig. 7c–d). However, the ABv treatment (with or without anti-
PD-1) efficiently prevented secondary tumor formation in the
adjuvant setting (Fig. 7c). Strikingly, after completion of the
adjuvant treatment, the ABv+IgG-treated mice soon started to
develop tumors; whereas, the ABv+anti-PD-1-treated mice
remained essentially tumor free (Fig. 7d–e). Only one mouse in
the latter group developed a tumor in one flank (Fig. 7e). Notably,
mice that received adjuvant venetoclax+anti-PD-1 treatment also
showed reduced tumor re-growth potential, suggesting that even
milder apoptosis induction by venetoclax alone could render
tumors susceptible to immunotherapy. All tumors were immu-
noprofiled after adjuvant treatment, and the lone tumor that
appeared in the ABv+anti-PD-1 cohort was biopsied. Whereas the
Fig. 3 AMPK activation upregulates BIM to sensitize cells to apoptosis. a AMPK activation does not alter the expression of anti-apoptotic BCL-2 family
proteins. MCF10A MycER cells were treated with vehicle or 1 μM A-769662. MYC was activated with 100 nM 4OHT for 24 h before the 24 h drug
treatment. b shRNA screen to determine pro-apoptotic regulators of MYC-dependent apoptosis. Left: Apoptosis induced by MYC and TRAIL in 3D
MCF10A acini. Right: shRNA-transduced cells were seeded into Matrigel to form acini and MycER was activated on day 20. The 3D acini were treated with
100 ng/ml of TRAIL for 72 h. Apoptosis was scored using active caspase-3 readout. Student’s t-test (unpaired), N= 3 biological replicates, SD. c The effect
of A-769662 on BIMEL and BIML expression. MYC was activated in MCF10A MycER for 24 h followed by 24 h treatment with 100 nM ABT-737, 1 μM A-
769662, or with combination. Lamin B: Loading control. d BIM knockdown blunts AMPK-mediated sensitization to apoptosis. MCF10A MycER shBIM cells
were treated as in c followed by quantitative analysis of apoptosis. Student’s t-test (unpaired), N= 3 biological replicates, SD. e Correlations between
nuclear MYC protein and BIM or AMPK activity (pACC) in breast cancer. Left: Representative images of BIM and pACC staining intensity groupings. Right:
High AMPK activity associates with elevated BIM expression in breast cancer. Blinded scoring of BIM and pACC levels, with intensities from 1 to 3 in a
breast cancer tissue microarray. f A model for AMPK-induced reactivation of MYC-dependent apoptosis in cancer. Acute: Acute activation of MYC
sensitizes cells to apoptosis via BIM-dependent modulation of the interactions between pro-apoptotic BAK/BAX and the anti-apoptotic BCL-2/XL proteins.
Likely, other BH3-only proteins also contribute to the apoptotic sensitization (dotted arrow). Pharmacological activation of AMPK enhances the BIM load in
MYC-overexpressing cells (red arrow), which together with inhibition of BCL-2/XL triggers apoptosis. Chronic: Tumors may escape AMPK-BIM pathway
via metabolic adaptation or by acquiring resistance mechanisms (thick dotted arrow), but the pro-apoptic pathway is still amenable to reactivation by
pharmacological AMPK activators
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ABv+IgG-treated tumors displayed reduction in active CD8+
cytotoxic T cells and minor changes in other lymphocyte subsets,
the biopsied sample from ABv+anti-PD-1-treated tumor showed
a general increase in the number of TILs and activity markers
(Fig. 7f). The ABv+anti-PD-1 treatment offered striking survival
benefit, with all the mice in the group surviving through the 30-
day follow-up period (Fig. 7g).
Next, we investigated the durability of the ABv+anti-PD-1
treatment response, extending the follow-up period to 60 days,
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paclitaxel and anti-PD-1 antibody. Taxanes (including paclitaxel)
are standard of care in the treatment of patients with breast
cancer and encouraging results were reported recently from the
Phase III IMpassion130 study, which included combination of
nab-paclitaxel plus the anti-PD-L1 antibody atezolizumab for
patients with advanced TNBC41. We noted that both ABv and
paclitaxel treatment caused low white blood cell counts (Fig. 7h);
however, only the paclitaxel+anti-PD-1 combination caused
significant elevation of alanine transaminase (ALAT), a marker of
liver injury (Fig. 7i). Tumor growth was clearly restricted in cohorts
that received either ABv+anti-PD-1 or paclitaxel+anti-PD-1
(Fig. 7j). Comparing the treatments, the therapeutic benefit was
similar in both tumor growth and survival analyses (Fig. 7j–k). One
cohort of ABv+anti-PD-1-treated mice was divided into two
smaller cohorts - one receiving three cycles of ABv+anti-PD-1 and
the other one cycle as in the previous experiment. Only one mouse
survived to the end of the 60-day follow-up period, and it had
received three cycles of ABv+anti-PD-1 (Fig. 7k). Although ABv
+anti-PD-1 treatment does not cure mice syngrafted with
aggressive tumors, these data indicate that it significantly delays
tumor re-growth and markedly improves their survival.
In conclusion, we propose that the combination of cell death-
inducing AB therapy together with anti-PD-1 immunotherapy
provides a potent tumor-targeting strategy with high translational
potential in tumor types with high MYC expression.
Discussion
MYC lacks the classical drug-binding sites of typical enzymes;
therefore, most therapeutic strategies have focused on inhibiting
its expression, stability or interaction with DNA binding part-
ners42. However, such approaches may come with unwanted side
effects, such as reduced sensitivity to front-line chemotherapies43.
Alternative, synthetic-lethal MYC-targeting (SL-MYC) approa-
ches aim to exploit MYC-dependent cancer vulnerabilities
without directly inhibiting MYC. For example, pharmacological
targeting of the spliceosome44, RhoA and SRF survival
signaling45,46, fatty acid oxidation47, or glutamine
metabolism12,48 induces MYC-selective apoptosis. Also MYC-
induced AMPK generates a cancer cell vulnerability via AMPK-
induced accumulation of mitochondrial p53, which binds to
and stimulates BAK activation22. While the concept of SL-MYC-
based cancer therapy is alluring based on MYC’s overexpression
across many cancer types, most currently available pharmacolo-
gical or biological agents with proven SL-MYC activity are not
suitable for testing in the clinic.
Here, we have established the strong pro-apoptotic and anti-
tumor potential of AMPK-activating molecules ex vivo and
in vivo. The pro-apoptotic activity of AMPK presents itself in a
specific context of high MYC expression and lowered BCL-2/
BCL-XL activity. The pro-apoptotic action of AMPK is coupled to
induction of the BH3-only protein BIM. BIM contains one of the
most potent BH3 death domains in the BCL-2 family, with a
capacity to engage all anti-apoptotic proteins with high affinity
and to activate death effectors, such as BAX49,50. Once activated,
BAX and BAK form pores in mitochondria to release cytochrome
c and other pro-apoptotic mediators into the cytosol51. While
earlier studies have shown that classical cell damage-associated
stress signaling and endoplasmic reticulum stress upregulates
BIM52, our results extend these findings to AMPK-dependent
stress signaling. In summary, pharmacological activation of
AMPK provides a tumor cell selective but otherwise non-
damaging route for induction of therapeutic apoptosis as a safer
alternative to more toxic agents. In our breast cancer TMA set
high MYC status did not correlate with high BIM expression or
high AMPK activity; however, high AMPK activity correlated
with high BIM expression. Thus, chronically elevated MYC levels
may not be able to sustain pro-apoptotic levels of AMPK-BIM
activity long-term and it is tempting to speculate that pharma-
cological stimulation of AMPK reactivates the MYC-associated
apoptotic machinery intrinsic to tumor cells (Fig. 3f). However,
the exact mechanistic role of MYC as a sensitizer of AMPK-
mediated tumor apoptosis remains to be clarified.
Our studies with an orally bioavailable ABn regimen (met-
formin+navitoclax) consistently demonstrated therapeutic
potential and efficacy in different models of MYC-overexpressing
breast cancer, including TNBC cell lines, breast cancer explants,
the WapMyc mouse model of breast adenocarcinoma, and
patient-derived xenografts. Notably, no therapeutic potential was
observed for the ABn regimen in two breast cancer models with
low MYC expression status. Metformin is an inexpensive insulin-
lowering drug with an excellent safety profile, which has made it
the most prescribed drug for type II diabetes. In addition to
metformin’s well-known antidiabetic activities, many epidemio-
logical and retrospective studies have suggested antitumoral
effects in cancers including breast cancer53,54. Metformin is an
antihyperglycaemic drug, which inhibits hepatic gluconeogenesis
in vivo through a LKB1/AMPK-dependent mechanism and via
inhibition of mitochondrial respiratory chain complex I55. With
regard to cancer, preclinical studies have suggested that the
tumor-preventing action of metformin is mediated through
activation of the AMPK pathway, which leads to suppression of
metabolic ATP-consuming processes such as glycolysis and fatty
acid oxidation54. These effects of metformin on cell energetics are
likely to impact tumor growth by mechanisms unrelated to
apoptosis and, indeed, we observed notable antitumoral effects in
the syngraft WapMyc model when metformin was administered
at a dose higher than the antidiabetic dose. However, we could
Fig. 4 AMPK activation combined with BCL-2/XL inhibition induces MYC-associated apoptosis in breast cancer patient-derived explant cultures.
aWorkflow for breast cancer patient tissue-derived explant cultures (PDEc). Tumor pieces were brought to the lab directly after surgery and cut into three
pieces; one for DNA/protein extraction, one for immunohistochemical (IHC) analyses and one for 3D culture. b IHC analysis of MYC in breast tumors.
Paraffin-embedded samples were immunostained for MYC and ≥5 fields of view (FOV) from 1 to 3 sections scored. MYC-high tumors: >50% positive
cells/FOV, MYC-low tumors: <20%-positive cells/FOV. N= 10 tumors. c Representative images of MYC-low and MYC-high PDEc cultures. The PDEc
samples were cultured for 7 days, stained and imaged by confocal microscopy (IF). d MYC status before and after 3D culture. MYC positivity scored as in
b. e ABT-737+A-769662-induced apoptosis in MYC-high, MYC-low, and non-cancerous (tumor adjacent tissue and reduction mammoplasty) PDEc
cultures. Samples were adjusted to culture for 6 days and treated for 24 h with vehicle (DMSO), 1 μM ABT-737, 10 μM A-769662 or ABT-737+A-769662
combination. The level of apoptosis was scored from confocal immunofluorescence images. The left panel shows representative images. The graphs
at right plot the quantification of apoptosis. Apoptosis was scored as 1= <10% apoptotic cells/explant, 2= >10% apoptotic cells/explant in a cohesive
structure, 3= >10% apoptotic cells/explant in a deteriorated structure. Each dot indicates one fragment. Horizontal lines: Average, Student’s t-test
(unpaired). f Summary of the apoptotic response in PDEc. Student’s t-test (unpaired). The different shades of green represent the different MYC-low
tumor samples, and the different shades of red represent the different MYC-high tumor samples. g AMPK activation upregulates BIM in PDEc culture.
pACC was used as an AMPK activity marker. The sample was treated with DMSO or 10 μM A-769662 for 24 h
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not observe any apoptotic effects when metformin was admi-
nistered alone. Therefore, metformin alone may not trigger
apoptosis, but has pro-apoptotic effects, via BIM upregulation,
which can be exploited therapeutically using BH3 mimetics.
We show that the strong induction of apoptosis by ABv treat-
ment (metformin+venetoclax) increases the density of tumor-
infiltrating lymphocytes (TILs). This effect was also observed in
tumors that developed after AB treatment, as indicated by
increased densities of NK and NKT cells expressing the CD107+
cytolytic marker. However, CD8+ T cells were decreased in the
post-treatment tumors and the remaining cells exhibited markers
of T-cell exhaustion56. These findings provided a rationale for
modified ABv therapy, which included an anti-PD-1 antibody as
the third component. In experiments using a revised ABv treat-
ment protocol, apoptosis was induced by ABv in a neoadjuvant
setting. After removal of the tumors, the treatment was continued
in the adjuvant setting using ABv together with anti-PD-1 anti-
body. Among all the treatment designs tested in the present study,
c
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only the ABv+anti-PD-1 regimen prevented all tumor-related
deaths during the 30-day experimental period. Only a single tumor
developed in one mouse of the ABv+anti-PD-1 group during the
post-treatment follow-up period and a biopsy of this tumor
showed enhanced densities of tumor-infiltrating lymphocytes. In
60-day follow-up the tumors eventually reappeared; nevertheless,
ABv+anti-PD-1 had similar or slightly enhanced antitumor
activity compared to paclitaxel+anti-PD-1, and it also showed less
signs of liver toxicity measured by plasma ALAT levels.
The durable efficacy of the ABv+anti-PD-1 treatment would
be consistent with a model, suggested by Sharma & Allison31 that
targeted therapies with strong apoptotic actions serve as “cancer
vaccines” by liberating tumor antigens and neoantigens from the
dying cancer cells. In this scenario, the role of checkpoint inhi-
bitors is to permit sustained T-cell responses. In support of this
notion, administration of anti-PD-1 antibody alone did not
inhibit tumor growth at all but showed remarkable efficacy when
administered together with ABv treatment.
In summary, we report here the discovery and preclinical
validation of a clinically applicable synthetic-lethal MYC-targeted
therapeutic strategy for the treatment of breast cancer. The ABv
+anti-PD-1 combination showed remarkable efficacy in a num-
ber of breast cancer models, which was somewhat surprising in
light of the fact that BCL-2 dependency is most often observed in
hematologic malignancies. The applicability of the ABv+anti-PD-
1 combination for treating other cancer types with high MYC and
BCL-2/BCL-XL status is currently being investigated in preclinical
models.
Methods
Transgenic animals. All animal experiments were approved by the National
Animal Ethics Committee of Finland (License number: ESAVI-3216/04.10.07/
2013), and the mouse colonies were maintained according to the protocols of the
Experimental Animal Committee of the University of Helsinki. FVB and WapMyc
mice (FVB.Cg-Tg(WapMyc)212Bri/J) were obtained from the Jackson Laboratory.
To activate Wap-promoter for tumorigenesis, WapMyc females of over 8-weeks of
age underwent two pregnancies. The drug treatments were started when the tumor
size reached Ø 5mm. For genotyping, DNA was extracted from tail samples with
DNAreleasy Kit (NIPPON Genetics EUROPE GmbH) according to the manu-
facturer’s protocol. The genotype was analyzed by PCR using the following pri-
mers: IMR0135 Fwd 5′-CATCCCTGTGACCCCTCC-3′ and IMR0136 Rev 5′-
CTCCAAACCACCCCCCTC-3′.
Patient-derived xenografts. The patient breast cancer samples for grafting were
received from Oncotest (now part of Charles River) and expanded once in NSG
mice (Charles River).
Mammary tumor transplantations. WapMyc tumors: For the procedure, 3-week-
old female FVB-recipient mice were given painkillers and anesthetized using
inhaled 2.5% isoflurane. Subsequently, the anterior part of 4th mammary gland was
cleared from the endogenous epithelium. 105 primary WapMyc tumor cells were
injected into the cleared gland in 10 μl of PBS supplemented with 5% FCS and the
wound was sealed with clips. The mice were given analgesics immediately after the
transplantation and monitored after the surgery. Drug treatment was started
1 week after the transplantations and the mice were treated and followed up as
detailed in the text. In the adjuvant treatment setting, the tumors were surgically
removed from the mice under isoflurane anesthesia, and the adjuvant treatment
was started after 3 days of recovery. Animals which formed tumors in the surgery
scar were excluded from the experiment.
MMTV-PyMT tumors: MMTV-PyMT tumor cells (kind gift from
Dr. Pauliina Kallio and Kari Alitalo, University of Helsinki) were syngrafted to
FVB hosts similarly as described in FVB WapMyc syngrafts. The tumor cells
were isolated from MMTV-PyMT donor and 106 cells were transplanted per
gland.
PDX tumors: TNBC-PDX transplantations were performed on immunocompromised
NOD scid gamma (NSG, NOD.Cg-PrkcdscidI12rgtm1Wjl/SzJ) obtained from
Charles River. For ER+PDX, 60-day 17β estradiol pellets (Innovative Research
America) were inserted into the neck of the animals to promote tumor growth.
Mice were killed when the tumor reached Ø 2 cm. Drug treatments were started
14 days after the transplantation. Tumor growth was monitored every second day.
Statistical modeling of tumor growth. The mice were randomized into treatment
groups and the tumor measurements were obtained with electronic caliper. The
results were averaged from two measurements performed by two individual
researchers. The formula for calculating tumor volume was V= d2 ×D/2, where
d= the shortest diameter and D= the longest. For statistical modeling of tumor
growth and treatment effect in the animal experiments, we used a mixed-effects
modeling framework that makes use of the whole longitudinal growth profile in
assessing the treatment and other fixed effects, while the random effects account for
individual tumor and animal-specific variation in growth patterns57. Moreover, the
categorizing mixed-effects model takes into account both the growing and stable or
poorly growing tumor sub-categories when testing treatment effects through model
parameters, such as tumor growth rates (slopes) or overall tumor levels (offset).
Drug treatments in mice. ABT-737: The mice were treated with either 100 mg/kg/
d ABT-737 solution or an equal volume of carrier solution administrated via
intraperitoneal injections (i.p.) for 21 consecutive days. ABT-737 was received from
Abbott (now AbbVie Inc). After the treatment the mice were followed up for
21 days. Navitoclax, venetoclax, metformin: The mice were treated with vehicle (5%
EtOH, 20% Phosal PG in MQ), 100 mg/kg/d navitoclax or venetoclax, 300 or 600 g/
kg/d metformin or with drug combinations delivered via intragastric (i.g.) route for
21 days. The cohorts were followed up until 60 days after transplantation. Navi-
toclax and venetoclax were from AbbVie Inc. Drugs were sonicated daily for better
solubility. In the experiments including anti-PD-1, mice received i.p. injections of
either 200 µg control IgG (bxcell, #BE0089) or 200 µg anti-PD-1 (bxcell, #BE0146)
every third day, in total four times, together with the 1-week daily adjuvant i.g.
treatments of either vehicle, venetoclax, metformin or the combination of vene-
toclax+metformin. Paclitaxel was administrated every third day, i.p., 10 mg/kg in
cremphor EL-ethanol-saline. Plasma ALAT levels were measured in the Bio-
chemical Analysis Core for Experimental Research, University of Helsinki.
Immunoprofiling of mouse peripheral blood samples. Peripheral blood samples
were collected from the tail vein of the mice (21-day drug treatments) into
Microtainer blood collection tubes (BD) after which the samples were stained with
CD45.1-APC-Cy7 (Biolegend, clone 30-F11, cat. 103116), CD3-APC (Biolegend,
clone 17A2, cat.100236), CD4-V500 (BD, clone RM4–5, cat. 560782), CD8b-FITC
(eBioscience, clone eBio H35–17.2, cat. 11–0083–85), NK1.1-PE (BD Biosciences,
clone PK136 cat. 557391) and red blood cells were lysed after with FACS lysing
Fig. 5 ABn treatment reduces viability of MYC-high triple-negative breast cancer cell lines, inhibits tumor growth, and extends survival in patient-derived
xenografts. a A summary of the results of BH3 mimetic screen in MCF10A MycER cells. The numbers refer to fold change as in Supplementary Figure 4A.
The drugs were navitoclax, venetoclax, a BCL-XL-selective inhibitor A-1155463 and an MCL-1-selective inhibitor A-1210477. b AB treatment-induces
apoptosis in MYC-high PDEc. The cultures were treated with DMSO, 1 μM navitoclax, 10mM metformin or combination for 24 h. Blinded scoring of
apoptosis was carried out for all samples. c MYC expression in 17 triple-negative breast cancer cell lines. MYC index: MYC intensity normalized to a blot-
to-blot reference sample, highest intensity band (HCC1599) and loading control. N.B. HCC1599 excluded from the final analysis due to poor growth.
Tubulin: Loading control. d The effect of AB treatment on the viability of MYC-low and MYC-high TNBC cell lines. The upper panel shows kill curves and
the dashed line marks the EC20 of navitoclax (20% reduction in survival); see also Fig.S4E. The lower panel shows metformin effect at EC20 of navitoclax.
Student’s t-test (unpaired), SD. e Summary table of drug treatments in TNBC cell lines. The cell lines were categorized according to MYC index (0=
undetectable MYC expression; + to +++= relative MYC expression level). Blue boxes indicate statistically non-significant and pink boxes statistically
significant differences between each single-agent treatment and the corresponding combination. Student’s t-test (unpaired). f Representative images of
tumors developing in TNBC-PDX mice. Black arrows: Primary tumors developing at the site of the tumor grafts; blue arrows: Metastases. g TNBC-PDX
tumors retain MYC expression during in vivo passaging. Tumor generations G1–G3. h Effect of AB treatment on tumor growth and survival in cohorts of
TNBC-PDX mice. The mice were treated with vehicle, 100mg/kg/d navitoclax, 600mg/kg/d metformin or the combination for 21 days, and followed up
until day 60. Student’s t-test (unpaired), SEM. In the survival graph: P-value: Significant difference between vehicle and AB-treated cohorts
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solution (BD). The samples were acquired with FACSVerse (BD Biosciences) and
analysed with FlowJo version 10.3 (TreeStar).
Immunoprofiling of mouse tumor samples. The tumor homogenate was stained
for immunophenotyping by flow cytometry in 3 different tubes each containing
0.067 g of the tumor mass. Following antibodies were used to stain the surface
markers: Tube 1: CD45-APC-Cy7, CD3-APC, CD4-V500, CD8b-FITC, PD-1-
PerCP-Cy5.5 (BioLegend, clone 29F.1A12, cat.135208), NK1.1-V450 (BD, clone
PK136, cat. 560524), CD107a-PE; Tube 2: CD45-APC-Cy7, CD3-APC, NK1.1-PE,
CD4-V500, CD8b-FITC, PD-1-PerCP-Cy5.5; Tube 3: CD45-PE (BD, clone 30-F11,
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(BD, clone 1A8, cat. 560602), Ly6C-AlexaFluor700 (BD, clone AL-21, cat. 561237),
PD-L1-BV421 (BD, clone MIH5, cat. 564716), CD86-APC (BD, clone GL1, cat.
558703) and CD80-PeCy7 (BioLegend, clone 16–10A1, cat. 104734). For intra-
cellular staining the cells from tube 2 were fixed and permeabilized with Cytofix/
Cytoperm (BD) according to the kit’s instructions and stained with IFN-γ-BV421
(BD, clone XMG1.2, cat. 563376) and Granzyme B-PeCy7 (eBiosciences, clone
NGZB, cat. 25–8898–82). Countbright beads (Life technologies) were added to the
sample tubes and the cell counts were normalized to 2000 beads counted during the
sample acquisition performed with FACSVerse BD. The data were analysed with
FlowJo version 10.3. Results are shown using the absolute number of cells, generally
excluding cells belonging to parental populations with less than 90 cells.
Patient-derived explants in 3D culture. Patient tumor samples were collected
from consenting patients with permission, approved by the Hospital District of
Helsinki and Uusimaa (Ethical permit: 243/13/03/02/2013). A small sample was cut
out from a primary tumor obtained from breast cancer surgery and transferred to
the laboratory, typically in less than 30 min. The sample was divided into three
parts: One part was snap frozen for DNA/protein analyses, one part was embedded
in paraffin for immunohistochemical analyses, and one part was processed for the
three-dimensional (3D) culture. The 3D culture sample was carefully minced with
a blade and incubated O/N with gentle shaking (130 rpm)+37 °C in Mammocult
basal medium (StemCell Technologies) containing 0.2% of Collagenase A (Sigma),
Mammocult proliferation supplements (StemCell Technologies), 4 μg/ml heparin,
0.48 μg/ml hydrocortisone, 50 μg/mL gentamicin, and penicillin/streptomycin (all
from Sigma). On the following day the mixture was centrifuged at 1400 rpm for
5 min and the pellet was resuspended in 5 ml PBS. Fragments were recentrifuged,
resuspended in Matrigel (BD) and seeded to 8-well chamber slides (Nunc) for 3D
culture. Samples were cultured in the Mammocult medium described above.
Breast cancer tissue microarrays. Breast cancer tissues of 285 women were
collected from the archives of the Department of Pathology, Helsinki University
Central Hospital. Tissue microarrays were constructed and molecular subtype
determined as described in detail earlier58. For the analyses, patients whose age at
the time of diagnosis or survival was not known, who had lobular or ductal car-
cinoma in situ, or whose immunohistochemical results for MYC staining were not
available or tissue array spot not representative of the tumor were excluded.
Altogether, 231 samples were available for analysis, with three replicate samples per
patient. BCL-2, BCL-XL, and MCL-1 were scored using reference images as a guide
to help the scoring. Human breast cancer TMA samples were obtained and used
under ethical permission (HUS 354/13/02/08).
Cell culture. MCF10A cells were obtained from ATCC and HEK293 cells were
provided by Prof. Timo Otonkoski (University of Helsinki). MCF10A MycER cells
(MycER being a tamoxifen inducible MYC fusion protein) have been previously
described14. MCF10A cells were cultured in epithelial cell basal medium MCDB
170 (US Biological) supplemented with 5 μg/mL insulin, 70 μg/mL Bovine Pituitary
Extract (BPE, Sigma), 0.5 μg/mL hydrocortison, 5 ng/mL epithelial growth factor
(EGF), 5 μg/mL human transferrin, 0.01 μM isoproterenol, and antibiotics.
HEK293 cells were cultured in DMEM with 10% FBS, L-glutamine and penicillin/
streptomycin.
TNBC cell line panel. A panel of 17 TNBC cell lines was obtained from ATCC
(ATCC-TCP-1003). Cell lines and culture medium compositions are presented in
Supplementary Table 2.
Induction of MYC with CRISPR/dead-Cas9. PiggyBac construct PB-tetON-
DDdCAS9VP192-T2A-GFP-IRES-Neo23 was modified to incorporate 2 additional
transactivation domains, p65 and HSF1, PCR-cloned from lenti sgRNA(MS2)_zeo
plasmid (Addgene, #61427,59). We designed five guide RNAs targeting the MYC
promoter, prepared gRNA-PCR transcriptional units and concatenated using
Golden Gate assembly. The concatenated MYC guide RNAs plasmid was cloned
into a PiggyBac backbone to obtain PB-GG-CMYC-PGK-Puro transposable plas-
mid. For the generation of a stable cell line with an inducible MYC dCas9-
activation system, cells were transfected or transduced with PB-tetON-
DDdCAS9VP192-p65-HSF1-T2A-GFP-IRES-Neo, PB-GG-MYC, and PB-CAG-
rtTA together with a PiggyBac-transposase plasmid, using FuGene HD (Promega).
After 72 h the cells were selected with G418 and puromycin. An inducible lentiviral
version of the dCas9-activator (FU_tetO_dCas9VP192-T2A-EGFP) was generated
by cloning dCas9VP192-T2A-EGFP fragment into an FUW-tetO lentiviral back-
bone (Addgene, #41084). We generated a lentiviral vector for the delivery of
sgMYC1 (LentigRNA_CMYC_1) by cloning MYC_1 transcriptional unit PCR
fragment into LentiCRISPR v2 backbone (Addgene, #52961). The sgRNA
sequences are shown in Supplementary Table 4.
Cell viability assays. TNBC cell lines were plated on poly-D-lysine coated 96-well
plates (354640, Corning BioCoat), 150 μl/well, and incubated at 37 °C for 24 h 50 μl
of 0.5% DMSO control, positive controls 0.05 ng/μl Nocodazole (S2775, Seleck-
chem), and 10 nM paclitaxel (S1150, Selleckchem), and navitoclax, metformin, A-
769662 (MedChemtronica) test concentrations were added to the cells in four
replicates, and the cells were treated for 72 h. For combination treatments navi-
toclax EC20 (unique for each cell line) concentration was tested in combination
with metformin and A-769662 test concentrations. Cell viability was determined by
adding 20 μl/well alamarBlue reagent (88952, Thermo Scientific). Fluorescence was
measured using a FLUORstar Omega plate reader, with 560 EX nm/590 EM filter
settings, 4 h, 6 h, and 8 h after alamarBlue addition.
Caspase-Glo® 3/7 Assay (Promega) was performed according to manufacturer’s
instructions and luminescence (RLU) was measured using VICTORTMx3 plate
reader (Perkin Elmer).
P53-long range PCR and sequencing from patient samples. KAPA Long Range
HotStart DNA Polymerase (KAPA Biosystems) was used to amplify the Tp53 gene
from the genomic DNA. Three PCR primer pairs were designed to cover the whole
Tp53 sequence. PCR products were purified with the Agencourt AMPure XP PCR
Purification systems (Beckman Coulter) and quantified using the Qubit dsDNA BR
Assay system (Invitrogen). The sequencing libraries were constructed with a
Nextera XT library preparation kit (Illumina) and the pooled, barcoded libraries
were subsequently sequenced using the MiSeq sequencer with 300PE reads. The
basic processing consisted of data quality analysis (FastQC), trimming of the poor
quality and adapter sequences (Trimmomatic), alignment of the sequences against
the hg19 reference genome using BWA (Burrows-Wheeler Aligner) and alignment
map sorting and duplicate identification by Picard tools (SAMTools). The actual
analysis consisted of GATK (the Genome Analysis Toolkit) with local realignment
around indels, base quality score recalibration, and variant calling, according to the
GATK Best Practices recommendations. Illumina VariantStudio was used to
annotate the SNPs and indels discovered. Sequencing primers are listed in Sup-
plementary Table 4.
Patient-derived xenograft sequencing. Total RNA was extracted from snap
frozen samples using the mirVana miRNA Isolation kit (Ambion, Carlsbad, CA)
according to the manufacturer’s instructions. Genomic DNA was removed using
the RNase-free DNaseSet (Qiagen). The quality of the RNA preparations was
controlled using a Bioanalyzer (Agilent Technologies). For DNA isolation, snap-
frozen tumor samples were digested with proteinase K at 55 °C overnight and
lysates were digested with RNase A (Qiagen). Next, the DNAs were extracted using
phenol:chloroform:isoamylalcohol and precipitated with ethanol. The DNA pellets
were washed and resuspended in TElow buffer (Tris 10 mM, pH 8, EDTA 0.1 mM,
pH 8). The integrity of the DNA samples was checked after 1.3% agarose gel
Fig. 6 ABn treatment inhibits tumor growth and extends survival of mice syngrafted with WapMyc tumors. a Combination treatment protocol for
orthotopically syngrafted WapMyc tumors. The mice were treated with a vehicle, navitoclax, and two concentrations of metformin alone or in combination
with navitoclax for 21 days. Immunoprofiling samples were collected right after the drug treatments or after a follow-up period. In the follow-up period the
samples were collected when the tumors reached Ø 2 cm and the mice had to be killed. b ABn treatment-induces BIM activation in vivo. The level of BIM
immunostaining was scored in IHC samples from treated tumors using a scale of 1–4 (representative examples are shown in the figure). The samples were
blinded for analysis. Student’s t-test (unpaired), SD. c ABn treatment-induced “apoptotic ponds”. Representative images of tumor samples stained for
cleaved caspase-3. d ABn treatment stimulates T-cell infiltration. WapMyc tumor samples were isolated from mice killed after the 21-day AB treatment
period. Representative images are shown and the data below show average and SD of CD4+ or CD8+ T cells in the tumors. Immunohistochemical
stainings were performed for at least 45 tumors per antibody and 3–6 field of view (fov) per tumor were analyzed. Student’s t-test (unpaired). e ABn
treatment-induced changes in proportions of peripheral lymphocytes. N (vehicle)= 7 mice, N (ABn)= 4 mice. Blood was collected after 21 days treatment
with either vehicle or ABn. Student’s t-test (unpaired), SD. f Tumor growth in ABn-treated mice. Student’s t-test (unpaired), SEM. g, h ABn treatment
extends survival. P-values: Difference between the vehicle and ABn-treated cohorts. i Flow cytometry-based immunoprofiling of vehicle and ABn
(navitoclax+metformin)-treated tumors. The heatmaps show fold-change compared to control. N= 6 (vehicle), N= 2 Navitoclax+Metformin. j Post-
treatment ratios of tumor-infiltrating PD-1+CD8+ T cells. Student’s t-test (unpaired), SD
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electrophoresis, and the purity of the DNA samples was determined using a
NanoDrop 2000 system (Thermo Scientific, Waltham, MA). All PDX models
were analyzed by Affymetrix HGU133 plus2.0, Affymetrix SNP6.0 and using
whole exome sequencing with Illumina HiSeq2000 at GATC (Konstanz,
Germany).
Immunohistochemistry. Tissues were collected and fixed with 4% paraformalde-
hyde (PFA) and embedded in paraffin. In all, 3–5 µm sections were cut and the
slides were deparafinized and incubated in 1X Antigen retrieval citrate buffer
solution (Dako) in +70 °C overnight. Histochemical stainings were carried out
using standard techniques. Images were taken with a Leica DM LB microscope and
Studio-Lite 1.0 software (Biomedicum Imaging Unit, University of Helsinki).
Images and slides were blinded for analysis.
Immunofluorescence stainings. Cells grown and treated on coverslips were fixed
with 4% PFA and permeabilized with 0.1% Triton X-100. 2D immunofluorescence
stainings were performed using standard protocols. 3D cultured patient samples
were fixed with 2% PFA, permeabilized with 0.25% Triton X-100, and blocked with
10% goat serum in PBS. Primary antibodies were diluted in blocking buffer and 3D
cultures were stained overnight. After three washes with IF buffer (0.1% BSA, 0.2%
Triton X-100, 0.05% Tween-20 in PBS), the structures were incubated with sec-
ondary antibodies in blocking buffer and washed again. Nuclei were counterstained
with Hoechst 33258 (Life Technologies) and mounted with Immu-Mount reagent
(Fisher Scientific). Imaging was performed using a Leica TCS CARS SP8 confocal
microscope (Biomedicum Imaging Unit, University of Helsinki).
Cell lysis and western blot. Isolated WapMyc tumor cells were lysed with non-
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Triton X-100, 10 mM NaPi, 10 mM Nappi). The lysed cells were incubated on
ice for 10 min and centrifuged at 13,400 rpm for 15 min at +4 °C. Snap-frozen
tissue samples (3 × 3 mm) were placed in homogenization tubes containing
ceramic beads (Bertin Technologies) and 300 µl of mammary gland lysis buffer
(10 mM Tris-HCl, pH 7.4 (HusLab), 150 mM NaCl (Sigma), 1% Triton X-100
(Sigma), 1 mM EDTA (Sigma), 1 mM EGTA (Sigma), 0.5% NP-40 (Fluka),
and 1 protease inhibitor coctail tablet (Roche) per 10 ml of solution) and
homogenized with Precelly’s homogenizer (Bertin Technologies). After
homogenization, the sample tubes were kept on ice for 30 min and then centrifuged
16,000 rpm for 30 min at +4 °C. The cultured cell lines were lysed with RIPA
lysis buffer. SDS-page and western blot were done using standard protocols.
Main manuscript western blots with original ladders are shown in Supplementary
Figure 6.
Annexin V/PI assay. WapMyc and normal porous cells were isolated from the
animals and cultured in low adhesion for 24 h and treated with drug treatments.
After treatments the samples were treated briefly with StemPro Accutase (Gibco) to
detach the cells from mammospheres. Cells and medium were collected and
Annexin V-FITC/PI assay was performed according to manufacturer’s instructions
(BioVision). Flow cytometry was performed using BD Accuri C6 flow cytometer in
Biomedicum FACS Core.
Antibodies. Antibodies used for western blot, immunohistochemistry, and
immunofluoresecence are shown in Supplementary Table 3.
Data analysis. GraphPad Prism 5 software was used for statistical analyses.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequencing data have been deposited to the Sequence Read Archive (SRA) with accession
number: SRP178687 (BioProject ID: PRJNA514437). Relevant manuscript data are
available from the authors upon request.
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